The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. — CFSMEATLAS
E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Standard · 3 min
The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample.
Neblett, Randy, Cohen, Howard, Choi, YunHee et al. · The journal of pain · 2013 · DOI
Quick Summary
This study tested a questionnaire called the Central Sensitization Inventory (CSI) to see if it could help doctors identify patients with conditions like ME/CFS, fibromyalgia, and irritable bowel syndrome. Researchers believe these conditions may share a common cause: the nervous system becoming overly sensitive to pain and other stimuli. The study found that a CSI score of 40 or higher was a good way to identify patients with these central sensitivity syndromes.
Why It Matters
For ME/CFS patients, this study provides evidence for a practical screening tool that could help with earlier identification and diagnosis of central sensitivity syndromes, which are often difficult to diagnose due to overlapping symptoms. Understanding central sensitization as a potential shared mechanism across ME/CFS, fibromyalgia, and related conditions may advance our understanding of disease etiology and support more targeted treatment approaches.
Observed Findings
74% of the pain center patient sample (89/121) met clinical criteria for one or more central sensitivity syndromes.
CSI scores were positively correlated with the number of diagnosed central sensitivity syndromes in the sample.
A CSI cutoff score of 40 achieved 81% sensitivity and 75% specificity for distinguishing CSS patients from nonclinical controls.
The area under the receiver operating characteristic curve was 0.86, indicating good discriminative ability.
Previous validation studies found the CSI to have high test-retest reliability (r=0.82) and internal consistency (Cronbach's α=0.88).
Inferred Conclusions
The CSI is a valid and reliable self-report screening instrument for identifying patients with central sensitivity syndromes, including fibromyalgia and chronic fatigue syndrome.
A cutoff score of 40 on the CSI provides clinically meaningful discrimination between patients with CSS and nonclinical populations.
Central sensitization may represent a shared physiological mechanism across multiple medically indistinct chronic pain and fatigue disorders.
Remaining Questions
Does the CSI perform equally well as a screening tool in primary care settings versus specialized pain centers?
What This Study Does Not Prove
This study does not prove that central sensitization causes ME/CFS or other central sensitivity syndromes—only that heightened central sensitivity is associated with these conditions. The cross-sectional design means we cannot determine whether abnormal nervous system sensitivity develops before or after disease onset. The study also does not establish the CSI's utility in primary care settings or its ability to predict treatment response or disease progression.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →